Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

420 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Drug sensitivity profiling of 3D tumor tissue cultures in the pediatric precision oncology program INFORM.
Peterziel H, Jamaladdin N, ElHarouni D, Gerloff XF, Herter S, Fiesel P, Berker Y, Blattner-Johnson M, Schramm K, Jones BC, Reuss D, Turunen L, Friedenauer A, Holland-Letz T, Sill M, Weiser L, Previti C, Balasubramanian G, Gerber NU, Gojo J, Hutter C, Øra I, Lohi O, Kattamis A, de Wilde B, Westermann F, Tippelt S, Graf N, Nathrath M, Sparber-Sauer M, Sehested A, Kramm CM, Dirksen U, Kallioniemi O, Pfister SM, van Tilburg CM, Jones DTW, Saarela J, Pietiäinen V, Jäger N, Schlesner M, Kopp-Schneider A, Oppermann S, Milde T, Witt O, Oehme I. Peterziel H, et al. Among authors: kallioniemi o. NPJ Precis Oncol. 2022 Dec 27;6(1):94. doi: 10.1038/s41698-022-00335-y. NPJ Precis Oncol. 2022. PMID: 36575299 Free PMC article.
Ex Vivo Drug Testing in Patient-derived Papillary Renal Cancer Cells Reveals EGFR and the BCL2 Family as Therapeutic Targets.
Angori S, Banaei-Esfahani A, Mühlbauer K, Bolck HA, Kahraman A, Karakulak T, Poyet C, Feodoroff M, Potdar S, Kallioniemi O, Pietiäinen V, Schraml P, Moch H. Angori S, et al. Among authors: kallioniemi o. Eur Urol Focus. 2023 Sep;9(5):751-759. doi: 10.1016/j.euf.2023.03.005. Epub 2023 Mar 16. Eur Urol Focus. 2023. PMID: 36933996 Free article.
Prediction model for drug response of acute myeloid leukemia patients.
Trac QT, Pawitan Y, Mou T, Erkers T, Östling P, Bohlin A, Österroos A, Vesterlund M, Jafari R, Siavelis I, Bäckvall H, Kiviluoto S, Orre LM, Rantalainen M, Lehtiö J, Lehmann S, Kallioniemi O, Vu TN. Trac QT, et al. Among authors: kallioniemi o. NPJ Precis Oncol. 2023 Mar 24;7(1):32. doi: 10.1038/s41698-023-00374-z. NPJ Precis Oncol. 2023. PMID: 36964195 Free PMC article.
The drug efficacy testing in 3D cultures platform identifies effective drugs for ovarian cancer patients.
Åkerlund E, Gudoityte G, Moussaud-Lamodière E, Lind O, Bwanika HC, Lehti K, Salehi S, Carlson J, Wallin E, Fernebro J, Östling P, Kallioniemi O, Joneborg U, Seashore-Ludlow B. Åkerlund E, et al. Among authors: kallioniemi o. NPJ Precis Oncol. 2023 Oct 31;7(1):111. doi: 10.1038/s41698-023-00463-z. NPJ Precis Oncol. 2023. PMID: 37907613 Free PMC article.
Drug repurposing platform for deciphering the druggable SARS-CoV-2 interactome.
Bogacheva MS, Kuivanen S, Potdar S, Hassinen A, Huuskonen S, Pöhner I, Luck TJ, Turunen L, Feodoroff M, Szirovicza L, Savijoki K, Saarela J, Tammela P, Paavolainen L, Poso A, Varjosalo M, Kallioniemi O, Pietiäinen V, Vapalahti O. Bogacheva MS, et al. Among authors: kallioniemi o. Antiviral Res. 2024 Mar;223:105813. doi: 10.1016/j.antiviral.2024.105813. Epub 2024 Jan 24. Antiviral Res. 2024. PMID: 38272320 Free article.
Delineating functional and molecular impact of ex vivo sample handling in precision medicine.
Struyf N, Österroos A, Vesterlund M, Arnroth C, James T, Sunandar S, Mermelekas G, Bohlin A, Hamberg Levedahl K, Bengtzén S, Jafari R, Orre LM, Lehtiö J, Lehmann S, Östling P, Kallioniemi O, Seashore-Ludlow B, Erkers T. Struyf N, et al. Among authors: kallioniemi o. NPJ Precis Oncol. 2024 Feb 19;8(1):38. doi: 10.1038/s41698-024-00528-7. NPJ Precis Oncol. 2024. PMID: 38374206 Free PMC article.
Drug response profiles in patient-derived cancer cells across histological subtypes of ovarian cancer: real-time therapy tailoring for a patient with low-grade serous carcinoma.
Murumägi A, Ungureanu D, Khan S, Arjama M, Välimäki K, Ianevski A, Ianevski P, Bergström R, Dini A, Kanerva A, Koivisto-Korander R, Tapper J, Lassus H, Loukovaara M, Mägi A, Hirasawa A, Aoki D, Pietiäinen V, Pellinen T, Bützow R, Aittokallio T, Kallioniemi O. Murumägi A, et al. Among authors: kallioniemi o. Br J Cancer. 2023 Feb;128(4):678-690. doi: 10.1038/s41416-022-02067-z. Epub 2022 Dec 7. Br J Cancer. 2023. PMID: 36476658 Free PMC article.
420 results